Who was studied, and how
One number in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 10 other studies
27,617people with cardiovascular disease, in this paper
The trial randomly assignedassigned by chance
semaglutide
placebo
Lowered major heart events−19%
randomisedthe abstract, start to end
… after administration of semaglutide (RR: 0.81, 95% CI: 0.74-0.88, p < 0.001, …
← favours treatmentfavours comparator →
could be chanceMajor adverse cardiovascular events (MACE)semaglutide vs placebo
RR 0.810.74–0.88
GLP-1 receptor agonistsCardiovascular events
GLP-1 receptor agonists × cardiovascular eventshelps?mixed
unlikelylikely
0.50not counted
← favours treatmentfavours comparator →
1 / 6